Moxetumomab Pasudotox: First Global Approval
Moxetumomab pasudotox-tdfk (LUMOXITI™), an anti CD22 recombinant immunotoxin, has been developed by MedImmune and its parent company AstraZeneca for the treatment of hairy cell leukaemia. The product, discovered at the National Cancer Institute, is an optimised version of immunotoxin CAT-3888. Moxetumomab pasudotox is composed of the Fv fragment of an anti-CD22 monoclonal antibody fused to a 38 kDa fragment of Pseudomonas exotoxin A, PE38. The Fv portion of moxetumomab pasudotox binds to CD22, a cell surface receptor expressed on a variety of malignant B-cells, thereby delivering the toxin moiety PE38 directly to tumour cells. Once internalised, PE38 catalyses the ADP ribosylation of the diphthamide residue in elongation factor-2 (EF-2), resulting in the rapid fall in levels of the anti-apoptotic protein myeloid cell leukaemia 1 (Mcl-1), leading to apoptotic cell death. This article summarizes the milestones in the development of moxetumomab pasudotox leading to this first approval for the treatment of adults with relapsed or refractory hairy cell leukaemia who received at least two prior systemic therapies, including treatment with a purine nucleoside analogue. Development of moxetumomab pasudotox for non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia and precursor cell lymphoblastic leukaemia/lymphoma was discontinued.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Sohita Dhillon is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 5.AstraZeneca. LUMOXITI™ (moxetumomab pasudotox-tdfk): US prescribing information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761104s000lbl.pdf. Accessed 4 Oct 2018.
- 6.FDA. FDA approves moxetumomab pasudotox-tdfk for hairy cell leukemia [media release]. 13 Sept 2018. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm620473.htm.
- 11.Kuruvilla D, Chia YL, Santiago L, et al. Efficacy and safety of moxetumomab pasudotox (moxe) in adult patients (pts) with relapsed/refractory Hairy Cell Leukemia (HCL) in relation to drug exposure, baseline disease burden, and immunogenicity [abstract no. 7060]. J Clin Oncol. 2018;36(15 Suppl).CrossRefGoogle Scholar
- 12.Balic K, Standifer N, Santiago L, et al. Pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of Moxetumomab pasudotox (Moxe), an immunotoxin targeting CD22, in adult patients (Pts) with relapsed or refractory Hairy Cell Leukemia (HCL) [abstract no. 7061]. In: 54th annual meeting of the American Society of Clinical Oncology. 2018.CrossRefGoogle Scholar
- 15.Kreitman R, Tallman MS, Robak T, et al. Negative minimal residual disease associated with extended response to moxetumomab pasudotox in patients with relapsed/refractory hairy cell leukemia: long-term follow-up of bone marrow immunohistochemistry analyses from a phase 1 study [abstract no. 2765]. Blood. 2017;130(Suppl 1).Google Scholar
- 16.Kreitman RJ, Arons E, Still K, et al. Moxetumomab pasudotox and minimal residual disease in hairy cell leukemia [abstract no. 7079]. J Clin Oncol. 2015;33(15 Suppl).Google Scholar